Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
about
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesDebate: Unstable angina - When should we intervene?Management of acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionUnstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapyGlycoprotein receptor inhibitors in the management of acute coronary syndromesAntiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?Role of abciximab in the treatment of coronary artery diseaseNon-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitionerUse of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis.Regular review: treatment possibilities for unstable angina.Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and EvaluatiPlatelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory?Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Volatile anesthetics, not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αIIbβ3.The role of pharmacotherapy and catheter-based intervention in the management of patients with non-ST-segment elevation acute coronary syndromes.The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention.Utilisation of coronary angiography after acute myocardial infarction in Ontario over time: have referral patterns changed?Plaque stabilisation by systemic and local drug administration.Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review.Peri-procedural myocardial injury: 2005 update.Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions.Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients.Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention.The evolution of antiplatelet therapy in cardiovascular disease.Anti-platelet therapy: glycoprotein IIb-IIIa antagonists2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiBleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?Drug-eluting coronary stents - focus on improved patient outcomes.
P2860
Q24202522-C2979D8B-8C8A-4D85-AA25-FD1211FFD844Q24202999-0B355CFE-9EBC-47A6-B694-DB0F070B6069Q24235385-68FF8660-6637-41AD-B1F5-755B2163D8FFQ24792327-99618A81-2E7F-43F6-99FC-F520A2FE6FBCQ28189763-5E0DF415-8873-4C1E-B888-81A50A789854Q28191096-DAB9DBCC-825E-4137-BA99-34B713206EE4Q28192025-43CD5168-0365-4011-ACE8-9CD0DC0AF09AQ28193156-7FC746FE-0C5A-4D5C-AA5C-9F90CBDFFCFDQ28193219-C4DB6587-8E15-41A9-A2CC-3DB3E34F13F7Q28200177-30648F01-2205-48A7-8836-DA3086340054Q28211708-39E31B9D-5797-456C-A73E-722FEBB483DBQ33369310-411200E4-BD1E-4594-9814-C0D80093519EQ33414284-20681B44-047D-4177-849E-313E90541F8FQ33802938-4D023BC6-08D5-479A-B51F-2E86AC149841Q33876187-6AF8E6A8-E3A6-4ABC-A1C9-C384058081EDQ34130613-4E47B605-59A3-48D4-92A3-A7EE71348EF8Q34336824-942A4AF2-80A1-4CCB-B0C8-A69EFB9422E6Q34445660-9C40A61F-B936-4713-8C74-A05B98FE048EQ34661939-D0A935EE-C588-4E76-9855-B18D9942B295Q34674157-BFA3AD2D-A76B-4E60-8AB7-A5D761A21AECQ34675290-3AFA649C-0F0E-4669-B956-B71782BEB2A5Q35580556-767BA7C4-8108-47C7-A2C2-66013AE97A8FQ35583277-94E9E178-BCA4-4A36-92F5-7EF834BF6CECQ35680598-48D93091-4D30-4BF6-82C2-D8788534E44BQ36263844-D465C73E-9E0E-4115-89A4-A5BFC95EE276Q36302146-CB715224-07CB-4CC4-98A4-A25F2C47C833Q36614135-8A5D37B3-FD76-4400-AAC8-06F72914C4F6Q36892804-4ECE18DC-7D5F-484E-95AD-C9F9C4FD0C75Q37048950-0596A52E-4829-40FD-9538-01A27235071BQ37255321-12404071-B807-477A-BF6D-E7848B7FDD6FQ37445883-DE49B8DF-49B7-4DAD-878A-12AA731AD77CQ37608567-5727EE9C-0B1D-4F77-A9FA-008E9D07B3A3Q37608580-EC7011C9-AC47-474A-97E8-7AB8C805795AQ37670997-9F86D75B-8F6F-4215-8CE6-547EF27E8FBCQ37683552-142DA61B-CD8A-4E0A-B6A8-2ABE2D954E8BQ37900470-1DFC244C-3B06-4D9E-BC6C-BCFCD69EF750Q37929839-BF8B9EBD-BCA6-44F3-BB70-D392D949F316Q37953885-208C6B13-8E51-40C5-BAE0-51DE10CCEC01Q38012078-D0957482-4AF2-40CF-85FE-052080BF8359Q38037077-15B28F4A-3DB1-4660-9F59-D0FD5975CA53
P2860
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@ast
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@en
type
label
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@ast
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@en
prefLabel
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@ast
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@en
P2093
P50
P1433
P1476
Platelet glycoprotein IIb/IIIa ...... taneous coronary intervention.
@en
P2093
K M Akkerhuis
M L Simoons
P304
P356
10.1161/01.CIR.100.20.2045
P407
P577
1999-11-01T00:00:00Z